BioNTech says no to Phase 3 with Genmab’s bispecific antibody
BioNTech has opted not to further contribute to a co-owned PD-L1 x 4-1BB bispecific antibody with Genmab, meaning the Danish biotech will have to move …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
